Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlpha Growth Regulatory News (ALGW)

Share Price Information for Alpha Growth (ALGW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.20
Bid: 1.10
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.20 (18.182%)
Open: 1.20
High: 1.20
Low: 1.20
Prev. Close: 1.20
ALGW Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Warrant Exercise and Total Voting Rights

15 Mar 2023 07:00

RNS Number : 9801S
Alpha Growth PLC
14 March 2023
 

 

Alpha Growth plc

("Alpha" or the "Company")

Exercise of Warrants, Issue of Equity for Expenses, and Total Voting Rights

Alpha Growth Plc (LSE: ALGW and OTCQB: ALPGF), a leading financial services specialist in the growing longevity asset class and insurance linked asset management, announces that it has received warrant exercise notices over an aggregate total of 18,750,000 ordinary shares of 0.1p each ("Ordinary Shares") in the Company for total consideration of £375,000.

In addition, the Company has issued 1,176,143 Ordinary Shares to certain advisers in lieu of expenses owed to them in relation to the Company's insurance business in 2022 at the closing price of 2.45p per Ordinary Share on 31 December 2022.

Application has been made for a total of 19,926,143 Ordinary Shares to be admitted to the standard listing segment of the Official List of the Financial Conduct Authority and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (together, "Admission"). Admission is expected to become effective at 8.00 a.m. on 20 March 2023.

Total Voting Rights

On Admission, the Company's issued share capital will consist of 451,813,531 Ordinary Shares. There are no Ordinary Shares held in treasury. Accordingly, the total number of voting rights in Alpha Growth plc at Admission will be 451,813,531.

The above figure 451,813,531 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Alpha Growth plc under the FCA's Disclosure Guidance and Transparency Rules.

** ENDS **

For more information, please visit www.algwplc.com or contact the following:

 

Alpha Growth plc

+44 (0) 20 3959 8600

Gobind Sahney, Executive Chairman

info@algwplc.com

 

Allenby Capital Limited

+44 (0) 20 3328 5656

Amrit Nahal (Sales and Corporate Broking)

Nick Athanas / Piers Shimwell (Corporate Finance)

 

UK Investor Relations - Mark Treharne

ir@algwplc.com

 

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, the Alpha Growth group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

Longevity Assets and Non-correlation

As a longevity asset, it is non-correlated to the real estate, equity capital and commodity markets. Its value is a function of time because as time passes the value gets closer to the face value of the policy. Hence creating a steady increase in the net asset value of the investment. This makes it highly attractive to investors wishing to counteract volatility within an investment portfolio and add yield.

Note: The Company only advises on and manages Longevity Assets that originate in the USA where the structured and life settlement market is highly regulated.

Forward Looking Statements Disclaimer

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward- looking statements, which speak only as of the date of this document. Readers should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences, including the merits of information and the risks. Readers of this announcement are advised to conduct their own due diligence and agree to be bound by the limitations of this disclaimer.

Important Notice

The content of this announcement has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (FSMA). This announcement has been issued by and is the sole responsibility of the Company. The information in this announcement is subject to change.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDGGDXXGBDGXS
Date   Source Headline
22nd Dec 20239:00 amRNSExpiration of Warrants
13th Dec 20237:00 amRNSAlpha International Life Receives KBRA Rating
14th Nov 20233:36 pmRNSJason Sutherland Receives Industry Recognition
9th Oct 20234:00 pmRNSHolding(s) in Company
9th Oct 20232:43 pmRNSHolding(s) in Company
29th Sep 202311:00 amRNSHalf-year Report
14th Aug 20236:29 pmRNSHolding(s) in Company
19th Jun 20237:00 amRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM
15th May 20237:00 amRNSAcquisition of Minority Holding and Share Issuance
3rd May 20237:00 amRNSHolding(s) in Company
2nd May 20237:00 amRNS2022 Annual Report & Financial Statements
15th Mar 20237:00 amRNSWarrant Exercise and Total Voting Rights
6th Mar 20237:00 amRNS2022 Annual Recap and Fund Results
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20231:10 pmRNSHolding(s) in Company
20th Jan 20232:05 pmRNSSecond Price Monitoring Extn
20th Jan 20232:00 pmRNSPrice Monitoring Extension
20th Jan 202311:05 amRNSSecond Price Monitoring Extn
20th Jan 202311:00 amRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSFurther Regarding Havelet Acquisition
6th Dec 20227:00 amRNSCompletion of Share Purchase Acquisition
17th Nov 20227:00 amRNSFinancial Services Company Acquistion
27th Oct 20227:00 amRNSChange of Adviser
26th Oct 20224:41 pmRNSSecond Price Monitoring Extn
26th Oct 20224:36 pmRNSPrice Monitoring Extension
3rd Oct 20224:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20224:35 pmRNSPrice Monitoring Extension
3rd Oct 20222:06 pmRNSSecond Price Monitoring Extn
3rd Oct 20222:00 pmRNSPrice Monitoring Extension
3rd Oct 202211:06 amRNSSecond Price Monitoring Extn
3rd Oct 202211:01 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
28th Sep 20227:00 amRNSAppointment as Investment Manager/Insurance Update
12th Sep 20222:06 pmRNSSecond Price Monitoring Extn
12th Sep 20222:00 pmRNSPrice Monitoring Extension
9th Sep 20222:06 pmRNSSecond Price Monitoring Extn
9th Sep 20222:00 pmRNSPrice Monitoring Extension
8th Sep 20227:00 amRNSDirector and Personnel Announcement
3rd Aug 20227:00 amRNSHolding(s) in Company
26th Jul 20224:40 pmRNSSecond Price Monitoring Extn
26th Jul 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20224:03 pmRNSResults of the Annual General Meeting
31st May 20227:00 amRNSRelease of 2021 Annual Report
27th Apr 20227:00 amRNSShareholder Information Update
24th Mar 20224:41 pmRNSSecond Price Monitoring Extn
24th Mar 20224:36 pmRNSPrice Monitoring Extension
24th Mar 20222:05 pmRNSSecond Price Monitoring Extn
24th Mar 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.